Figure 1

Tumor type specific cytotoxic T lymphocyte activity induced by Adel55-cHSF1 administration. Established subcutaneously B16 tumors were treated by intratumoral injection of PBS, or 5 × 10⁸ pfu Adel55, Adel55-cHSF1 or Adel55-HSF1i. Splenocytes from resistant and non-resistant animals were obtained two weeks after the second tumor challenge and restimulated with mitomycin C-treated B16 cells as effector cells. The effector cells were then assayed for cytolytic function by using B16 (A) or CT26 (B) cells as targets. The ratio 25, 50 and 100 of effector/target cells were detected. Percent specific lysis of target cells is depicted on the y-axis. All results are shown as mean ± SD (n = 5). Similarly, established subcutaneously CT26 tumors were treated by intratumoral injection of PBS, or 5 × 10⁸ pfu Adel55, Adel55-cHSF1 or Adel55-HSF1i. Splenocytes from resistant and non-resistant animals were obtained two weeks after the second tumor challenge and restimulated with mitomycin C-treated CT26 cells as effector cells. The effector cells were then assayed for cytolytic function by using CT26 (C) or B16 (D) cells as targets.